Noscira receives FDA approval for Tideglusib drug to treat PSP

Links shared publicly online about this topic.

884
total visits

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira, a Grupo Zeltia subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder.

View full resource at news-medical.net

Tags: Disease and Condition, Diet and Nutrition, Drug, FDA, Oncology, News, disease